Researchers have discovered that a rabbit virus can deliver a one-two punch, killing some kinds of cancer cells while eliminating a common and dangerous complication of bone marrow transplants.
A short course of cyclophosphamide can not only prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate need for the typical 6-month round of immune suppression medicines.
A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a new study from researchers.
The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.
Vorinostat, already used in lymphoma, reduces the risk of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.
Among patients who receive either peripheral blood stem cells (PBMCs) or bone marrow from unrelated donors, the incidence of overall chronic graft-versus-host-disease (GVHD; 53%) is higher in those who received PBMCs than in those who received bone marrow stem cells (40%).
A new mathematical model suggests that proper risk assessment for the risk of infection with cancer chemotherapy needs to evaluate both the quantity and quality of white blood cells. The model was built by Weizmann Institute mathematicians in collaboration with physicians from the Meir Medical Center in Kfar Saba and from the Hoffman-La Roche research center in Basel, Switzerland.
A certification program in blood and marrow transplantation nursing is being offered by the Oncology Nursing Certification Corporation, with the first BMTCN examination scheduled for February 2014.
An HIV drug helped lower the risk of graft-versus-host disease in persons with blood cancer who had stem-cell transplants to rebuild bone marrow.
Persons aged 16-39 with acute lymphoblastic leukemia fared better with pediatric-inspired chemotherapy regimens than with typical adult treatment.
